PainReform Completes Enrollment In Second Part Of Its Phase 3 Bunionectomy Trial For PRF-110
Portfolio Pulse from Benzinga Newsdesk
PainReform Ltd. (NASDAQ:PRFX) has completed patient enrollment for the second part of its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate for post-operative pain. A total of 428 patients have been enrolled across eight U.S. clinical sites.
June 26, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PainReform Ltd. has completed patient enrollment for its Phase 3 clinical trial of PRF-110, marking a significant milestone towards the drug's registration.
The completion of patient enrollment in a Phase 3 trial is a critical step towards drug approval and commercialization. This milestone is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100